HomeQuestion
Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?
1
1 Answers
Mednet Member
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Excellent question - to add citations for those who missed ASCO 2024 (I did since I was on inpatient!) and would like to jump to the manuscripts:
- IMROZ: Isa-VRd versus VRd (Facon et al., PMID 38832972)
- BENEFIT/IFM 2020-05: Isa-VRd versus Isa-Rd (Leleu et al., PMID 38830994)
Both trials enrolled pati...